Can COVID Vaccine Latecomer Ocugen Beat Pfizer and Moderna?

Several days ago, Ocugen (NASDAQ: OCGN) was an early-stage biotech company focusing on gene therapy to cure eye diseases. And then everything changed. All of a sudden, investors began piling into the shares, and the company joined the center stage of the stock market with the likes of Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).

That's because Ocugen finalized a deal to co-develop and commercialize Indian company Bharat Biotech's late-stage investigational coronavirus vaccine in the U.S. The biggest gain didn't follow the announcement, though. It came after Ocugen raised $23 million at a considerable premium to fund the project. As a result, the stock soared more than 200% in one trading session. Now the question is whether the Ocugen/Bharat vaccine candidate's efficacy can beat that of today's vaccines -- those of Pfizer and Moderna. Let's take a closer look.

Image source: Getty Images.

Continue reading

Source Fool.com